Skip to main content
Search

Biosimilars: when value meets cost

Published on March 30, 2023   25 min

A selection of talks on Clinical Practice

Please wait while the transcript is being prepared...
0:00
Hello, I am Fernando de Mora Professor of Pharmacology at a fairly big Spanish University called Universidad Autónoma de Barcelona, a public University. I have been asked to deliver a talk on biosimilars and try to convey the message that volume meets costs in that case.
0:20
So the message that I want to deliver would be biosimilar, in fact, is a biological medicine. that shares the active substance with an original biologic. It is administered by the same route, at the same dose, and for the same indications. What I want to do is I want to try to help you understand why can we conclude this?
0:43
We will address this issue by discussing four topics. I will start with explaining what is a biologic medicine vs non-biological medicine.
0:54
Well, let's assume for the purpose of this talk that a biologic is just a medicine, obtained from a living organism. If we go to legal definitions, that is far more complicated. But we can consider that whenever a living organism is producing the medicine, it is a biologic medicine. For instance, insulin from the pancreas. That was at that time a biologic medicines. But we can also obtain biologic medicines from human sources. For instance, factor VIII. If I get the blood, extract blood from healthy volunteers, I can isolate the coagulation factor VIII and use it in hemophilic patients. Now, is there an alternative source of this human factor VIII? Indeed there is.

Quiz available with full talk access. Request Free Trial or Login.